JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

Lisata Therapeutics

Geschlossen

2.78 2.96

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.5

Max

2.7800000000000002

Schlüsselkennzahlen

By Trading Economics

Angestellte

26

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+435.71% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

11. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

261K

21M

Vorheriger Eröffnungskurs

-0.18

Vorheriger Schlusskurs

2.78

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Okt. 2025, 23:50 UTC

Heiße Aktien

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28. Okt. 2025, 23:25 UTC

Ergebnisse

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28. Okt. 2025, 23:18 UTC

Ergebnisse

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28. Okt. 2025, 22:20 UTC

Ergebnisse

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28. Okt. 2025, 22:13 UTC

Ergebnisse

Wal-Mart de Mexico Net Profit Falls in 3Q

28. Okt. 2025, 21:38 UTC

Ergebnisse

Correction to Visa Sales Jump Article

28. Okt. 2025, 21:17 UTC

Ergebnisse

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28. Okt. 2025, 21:07 UTC

Ergebnisse

Visa Sales Jump as Consumers Keep Spending -- Update

28. Okt. 2025, 21:02 UTC

Ergebnisse

Mondelez Tempers Outlook as Costs Rise

28. Okt. 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28. Okt. 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28. Okt. 2025, 23:02 UTC

Ergebnisse

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28. Okt. 2025, 23:01 UTC

Ergebnisse

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28. Okt. 2025, 22:46 UTC

Ergebnisse

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28. Okt. 2025, 22:45 UTC

Ergebnisse

SK Hynix 3Q Net KRW12.6T >000660.SE

28. Okt. 2025, 22:44 UTC

Ergebnisse

SK Hynix 3Q Rev KRW24.44T >000660.SE

28. Okt. 2025, 22:43 UTC

Ergebnisse

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28. Okt. 2025, 22:42 UTC

Ergebnisse

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28. Okt. 2025, 22:40 UTC

Ergebnisse

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28. Okt. 2025, 22:40 UTC

Ergebnisse

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28. Okt. 2025, 22:22 UTC

Ergebnisse

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28. Okt. 2025, 22:22 UTC

Ergebnisse

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28. Okt. 2025, 22:22 UTC

Ergebnisse

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28. Okt. 2025, 22:20 UTC

Ergebnisse

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28. Okt. 2025, 22:02 UTC

Ergebnisse

Review & Preview: Earnings Extravaganza -- Barrons.com

28. Okt. 2025, 21:42 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

28. Okt. 2025, 21:42 UTC

Market Talk
Ergebnisse

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28. Okt. 2025, 21:20 UTC

Ergebnisse

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28. Okt. 2025, 21:19 UTC

Ergebnisse

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28. Okt. 2025, 21:18 UTC

Ergebnisse

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Kursziel

By TipRanks

435.71% Vorteil

12-Monats-Prognose

Durchschnitt 15 USD  435.71%

Hoch 15 USD

Tief 15 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lisata Therapeutics – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Finanzen

$

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
help-icon Live chat